eicosanoid


Also found in: Medical, Encyclopedia, Wikipedia.

ei·co·sa·noid

 (ī′kō-sə-noid′)
n.
Any of a group of substances that are derived from arachidonic acid, including leukotrienes, prostaglandins, and thromboxanes.

[eicosan(e), chemical name (Greek eikosi, twenty, from its twenty carbon atoms; see wīkm̥tī- in Indo-European roots + -ane) + -oid.]

eicosanoid

(aɪˈkəʊsəˌnɔɪd)
n
any of a group of compounds, including the leukotrienes and the prostglandins, which are produced by the oxygenation of essential fatty acids and which are involved in a range of physiological processes, including inflammation and immunity
References in periodicals archive ?
Sebaldt RJ, Sheller JR, Oates JA, et al Inhibition of eicosanoid biosynthesis by glucocorticoid in humans.
Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids.
Oral green tea catechin metabolites are incorporated into human skin and protect against UV radiation-induced cutaneous inflammation in association with reduced production of pro-inflammatory eicosanoid 12-hydroxyeicosatetraenoic acid.
For quantitative catecholamine and eicosanoid determination, the limit of detection or quantification was determined from the daily calibration curve, and absolute quantification was performed with stable isotope-labeled standards.
Omega-3 fatty acids regulate the production of eicosanoid in the human body.
These mechanisms of n-3 PUFA regulate inflammation via the eicosanoid pathway[sup.
The reduction of eicosanoid release was related to the inhibition of cyclooxygenase-2 expression.
The regulation of eicosanoid production occurs, in part, via the coordinated spatial-temporal expression of associated enzymatic pathways that vary according to cell type and upon the state of cellular activation.
Omega-3 and some omega-6 (eg GLA) FFAs generate anti-inflammatory mediators via the eicosanoid pathways.
Ongoing investigations of eicosanoid metabolites in the laboratory have led to the discovery of novel therapeutic targets for cardiovascular diseases.
Prostaglandins and leukotrienes: Advances in eicosanoid biology.
Prostacyclin opposes the effects of thromboxane, a thrombogenic and atherogenic eicosanoid.